These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30383732)

  • 1. Osmolex ER--another extended-release amantadine for Parkinson's disease.
    Med Lett Drugs Ther; 2018 Sep; 60(1555):148-150. PubMed ID: 30383732
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison chart: Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1618):25-32. PubMed ID: 33647001
    [No Abstract]   [Full Text] [Related]  

  • 4. Istradefylline (Nourianz) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
    LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
    Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 7. Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
    Marmol S; Feldman M; Singer C; Margolesky J
    CNS Drugs; 2021 Nov; 35(11):1141-1152. PubMed ID: 34648150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiating therapy for Parkinson's disease.
    Silver DE; Ruggieri S
    Neurology; 1998 Jun; 50(6 Suppl 6):S18-22; discussion S44-8. PubMed ID: 9633682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amantadine Extended-Release (GOCOVRI
    Paik J; Keam SJ
    CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy for patients with early-stage Parkinson's disease].
    Tanaka M; Okamoto K
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1426-31. PubMed ID: 13677890
    [No Abstract]   [Full Text] [Related]  

  • 13. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084
    [No Abstract]   [Full Text] [Related]  

  • 14. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
    Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
    J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.
    Snineh MA; Hajyahya A; Linetsky E; Eitan R; Bergman H; Israel Z; Arkadir D
    J Parkinsons Dis; 2020; 10(1):173-178. PubMed ID: 31868682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
    Frampton JE
    Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
    Hauser RA; Pahwa R; Wargin WA; Souza-Prien CJ; McClure N; Johnson R; Nguyen JT; Patni R; Went GT
    Clin Pharmacokinet; 2019 Jan; 58(1):77-88. PubMed ID: 29777529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review on initial drug treatment in Parkinson's disease did not mention entacapone.
    Elrington GM
    BMJ; 2015 Nov; 351():h5843. PubMed ID: 26530214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.